Dihua Yu - Publications

The University of Texas Graduate School of Biomedical Sciences at Houston 
Molecular Biology, Cell Biology

97 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, ... ... Yu D, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. The Journal of Clinical Investigation. PMID 29130936 DOI: 10.1172/JCI91553  0.56
2017 Yang J, Joshi S, Wang Q, Li P, Wang H, Xiong Y, Xiao Y, Wang J, Parker-Thornburg J, Behringer RR, Yu D. 14-3-3ζ loss leads to neonatal lethality by microRNA-126 downregulation-mediated developmental defects in lung vasculature. Cell & Bioscience. 7: 58. PMID 29118970 DOI: 10.1186/s13578-017-0186-y  0.52
2017 Wang X, Yao J, Wang J, Zhang Q, Brady SW, Arun B, Seewaldt V, Yu D. Targeting Aberrant p70S6K Activation for Estrogen Receptor Negative Breast Cancer Prevention. Cancer Prevention Research (Philadelphia, Pa.). PMID 28877935 DOI: 10.1158/1940-6207.CAPR-17-0106  0.56
2017 Joshi S, Yang J, Wang Q, Li P, Wang H, Zhang Q, Xiong Y, Pickering BF, Parker-Thornburg J, Behringer RR, Yu D. 14-3-3ζ loss impedes oncogene-induced mammary tumorigenesis and metastasis by attenuating oncogenic signaling. American Journal of Cancer Research. 7: 1654-1664. PMID 28861322  0.52
2016 Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, Kim T, Chang WC, Hsu JL, Yamaguchi H, Ding Q, ... ... Yu D, et al. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. PMID 27866850 DOI: 10.1016/j.ccell.2016.10.010  0.44
2016 Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Ding Q, ... ... Yu D, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nature Communications. 7: 12632. PMID 27572267 DOI: 10.1038/ncomms12632  0.56
2016 Chang CC, Zhang C, Zhang Q, Sahin O, Wang H, Xu J, Xiao Y, Zhang J, Rehman SK, Li P, Hung MC, Behbod F, Yu D. Upregulation of lactate dehydrogenase a by 14-3-3ζ leads to increased glycolysis critical for breast cancer initiation and progression. Oncotarget. PMID 27150057 DOI: 10.18632/oncotarget.9136  0.52
2015 Rahal OM, Nie L, Chan LC, Li CW, Hsu YH, Hsu J, Yu D, Hung MC. Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells. American Journal of Cancer Research. 5: 3624-34. PMID 26885451  0.44
2015 Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang WC, Li P, Li M, Wang X, Zhang C, Wang H, Ellis K, Cheerathodi M, McCarty JH, Palmieri D, ... ... Yu D, et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. PMID 26479035 DOI: 10.1038/nature15376  0.36
2015 Jain S, Wang X, Chang CC, Ibarra-Drendall C, Wang H, Zhang Q, Brady SW, Li P, Zhao H, Dobbs J, Kyrish M, Tkaczyk TS, Ambrose A, Sistrunk C, Arun B, ... ... Yu D, et al. Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer. Cancer Research. PMID 26383165 DOI: 10.1158/0008-5472.CAN-14-2345  0.52
2015 Brady SW, Zhang J, Tsai MH, Yu D. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. Cancer Biology & Therapy. 16: 402-11. PMID 25692408 DOI: 10.1080/15384047.2014.1002693  0.36
2015 Xu J, Acharya S, Sahin O, Zhang Q, Saito Y, Yao J, Wang H, Li P, Zhang L, Lowery FJ, Kuo WL, Xiao Y, Ensor J, Sahin AA, Zhang XH, ... ... Yu D, et al. 14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. Cancer Cell. 27: 177-92. PMID 25670079 DOI: 10.1016/j.ccell.2014.11.025  0.56
2015 Momeny M, Saunus JM, Marturana F, McCart Reed AE, Black D, Sala G, Iacobelli S, Holland JD, Yu D, Da Silva L, Simpson PT, Khanna KK, Chenevix-Trench G, Lakhani SR. Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget. 6: 3932-46. PMID 25668816  0.36
2015 Boulbes DR, Arold ST, Chauhan GB, Blachno KV, Deng N, Chang WC, Jin Q, Huang TH, Hsu JM, Brady SW, Bartholomeusz C, Ladbury JE, Stone S, Yu D, Hung MC, et al. HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Molecular Oncology. 9: 586-600. PMID 25435280 DOI: 10.1016/j.molonc.2014.10.011  0.36
2014 Khotskaya YB, Goverdhan A, Shen J, Ponz-Sarvise M, Chang SS, Hsu MC, Wei Y, Xia W, Yu D, Hung MC. S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. American Journal of Translational Research. 6: 361-76. PMID 25075253  0.44
2014 Thirumurthi U, Shen J, Xia W, LaBaff AM, Wei Y, Li CW, Chang WC, Chen CH, Lin HK, Yu D, Hung MC. MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. Science Signaling. 7: ra71. PMID 25074979 DOI: 10.1126/scisignal.2005076  0.44
2014 Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, ... ... Yu D, et al. Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Research. 74: 4822-35. PMID 24970481 DOI: 10.1158/0008-5472.CAN-14-0584  0.36
2014 Sahin O, Wang Q, Brady SW, Ellis K, Wang H, Chang CC, Zhang Q, Priya P, Zhu R, Wong ST, Landis MD, Muller WJ, Esteva FJ, Chang J, Yu D. Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Research. 24: 542-59. PMID 24675532 DOI: 10.1038/cr.2014.37  0.36
2014 Rehman SK, Li SH, Wyszomierski SL, Wang Q, Li P, Sahin O, Xiao Y, Zhang S, Xiong Y, Yang J, Wang H, Guo H, Zhang JD, Medina D, Muller WJ, ... Yu D, et al. 14-3-3ζ orchestrates mammary tumor onset and progression via miR-221-mediated cell proliferation. Cancer Research. 74: 363-73. PMID 24197133 DOI: 10.1158/0008-5472.CAN-13-2016  0.36
2013 Saldana SM, Lee HH, Lowery FJ, Khotskaya YB, Xia W, Zhang C, Chang SS, Chou CK, Steeg PS, Yu D, Hung MC. Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis. Plos One. 8: e73406. PMID 24039934 DOI: 10.1371/journal.pone.0073406  0.44
2013 Kyrish M, Dobbs J, Jain S, Wang X, Yu D, Richards-Kortum R, Tkaczyk TS. Needle-based fluorescence endomicroscopy via structured illumination with a plastic, achromatic objective. Journal of Biomedical Optics. 18: 096003. PMID 24002190 DOI: 10.1117/1.JBO.18.9.096003  0.36
2012 Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, Huang HY, Tsai KKC, Flores LG, Shao Y, Hazle JD, Yu D, Wei W, Sarbassov D, Hung MC, et al. The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis. Cell. 151: 913-914. PMID 30360292 DOI: 10.1016/j.cell.2012.10.025  0.44
2012 Wang Q, Li SH, Wang H, Xiao Y, Sahin O, Brady SW, Li P, Ge H, Jaffee EM, Muller WJ, Hortobagyi GN, Yu D. Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Research. 72: 4417-28. PMID 22773664 DOI: 10.1158/0008-5472.CAN-12-1339-T  0.52
2012 Tan M, Yu D, Jin Y, Dou L, Li B, Wang Y, Yue J, Liang L. An information transmission model for transcription factor binding at regulatory DNA sites. Theoretical Biology & Medical Modelling. 9: 19. PMID 22672438 DOI: 10.1186/1742-4682-9-19  1
2012 Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, Hazle JD, Yu D, Wei W, Sarbassov D, Hung MC, et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell. 149: 1098-111. PMID 22632973 DOI: 10.1016/j.cell.2012.02.065  0.36
2012 Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF, Wulfkuhle J, Liotta LA, Lem S, Baker JC, Ford AC, Wilke LG, Zalles C, Kuderer NM, Hoffman AW, Shivraj M, ... ... Yu D, et al. Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. Breast Cancer Research and Treatment. 132: 487-98. PMID 21647677 DOI: 10.1007/s10549-011-1609-9  0.36
2011 Pickering BF, Yu D, Van Dyke MW. Nucleolin protein interacts with microprocessor complex to affect biogenesis of microRNAs 15a and 16. The Journal of Biological Chemistry. 286: 44095-103. PMID 22049078 DOI: 10.1074/jbc.M111.265439  0.36
2011 Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, Yamaguchi H, Xie X, Woodward WA, Yu D, Hortobagyi GN, Hung MC. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell. 20: 341-56. PMID 21907925 DOI: 10.1016/j.ccr.2011.07.017  0.44
2011 Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nuñez R, Hortobagyi GN, ... Yu D, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3126-32. PMID 21730275 DOI: 10.1200/JCO.2010.32.2321  0.36
2011 Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, Sahin AA, Esteva FJ, Hortobagyi GN, Yu D. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature Medicine. 17: 461-9. PMID 21399647 DOI: 10.1038/nm.2309  0.36
2011 Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH, Liu M, Chen CT, Yu D, Hung MC. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nature Cell Biology. 13: 317-23. PMID 21336307 DOI: 10.1038/ncb2173  0.44
2011 Pierce M, Yu D, Richards-Kortum R. High-resolution fiber-optic microendoscopy for in situ cellular imaging. Journal of Visualized Experiments : Jove. PMID 21248707 DOI: 10.3791/2306  0.36
2011 Pilie PG, Ibarra-Drendall C, Troch MM, Broadwater G, Barry WT, Petricoin EF, Wulfkuhle JD, Liotta LA, Lem S, Baker JC, Stouder A, Ford AC, Wilke LG, Zalles CM, Mehta P, ... ... Yu D, et al. Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 20: 476-82. PMID 21242333 DOI: 10.1158/1055-9965.EPI-10-0847  0.36
2011 Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Research. 71: 603-13. PMID 21123450 DOI: 10.1158/0008-5472.CAN-10-3185  0.36
2010 Neal CL, Yu D. 14-3-3ζ as a prognostic marker and therapeutic target for cancer. Expert Opinion On Therapeutic Targets. 14: 1343-54. PMID 21058923 DOI: 10.1517/14728222.2010.531011  0.36
2010 Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochemical and Biophysical Research Communications. 403: 103-7. PMID 21040707 DOI: 10.1016/j.bbrc.2010.10.126  0.52
2010 Baker EL, Lu J, Yu D, Bonnecaze RT, Zaman MH. Cancer cell stiffness: integrated roles of three-dimensional matrix stiffness and transforming potential. Biophysical Journal. 99: 2048-57. PMID 20923638 DOI: 10.1016/j.bpj.2010.07.051  0.52
2010 Cheng X, Xia W, Yang JY, Hsu JL, Lang JY, Chou CK, Du Y, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis. Cancer Research. 70: 7684-9. PMID 20841468 DOI: 10.1158/0008-5472.CAN-09-3231  0.52
2010 Lu J, Yu D. Invasive breast cancer development: "fatal accident" from malfunctions in both "motor" and "brake". Cell Cycle (Georgetown, Tex.). 9: 421-2. PMID 20090417 DOI: 10.4161/cc.9.3.10633  0.52
2010 Esteva FJ, Yu D, Hung MC, Hortobagyi GN. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nature Reviews. Clinical Oncology. 7: 98-107. PMID 20027191 DOI: 10.1038/nrclinonc.2009.216  0.44
2009 Li SH, Hawthorne VS, Neal CL, Sanghera S, Xu J, Yang J, Guo H, Steeg PS, Yu D. Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-kappaB activation. Cancer Research. 69: 9163-8. PMID 19951994 DOI: 10.1158/0008-5472.CAN-09-2483  0.36
2009 Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B, Ling C, Zhou X, Chen T, Chiao PJ, Feng X, Seewaldt VL, Muller WJ, Sahin A, Hung MC, ... Yu D, et al. 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell. 16: 195-207. PMID 19732720 DOI: 10.1016/j.ccr.2009.08.010  0.52
2009 Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu D, Fodstad O, Tan M. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene. 28: 3689-701. PMID 19668225 DOI: 10.1038/onc.2009.229  1
2009 Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, Cristofanilli M, Dontu G, Bidaut L, Valero V, Hortobagyi GN, Yu D. Breast cancer metastasis: challenges and opportunities. Cancer Research. 69: 4951-3. PMID 19470768 DOI: 10.1158/0008-5472.CAN-09-0099  0.36
2009 Hawthorne VS, Huang WC, Neal CL, Tseng LM, Hung MC, Yu D. ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. Molecular Cancer Research : McR. 7: 592-600. PMID 19372587 DOI: 10.1158/1541-7786.MCR-08-0316  0.36
2009 Kligys K, Yao J, Yu D, Jones JC. 14-3-3zeta/tau heterodimers regulate Slingshot activity in migrating keratinocytes. Biochemical and Biophysical Research Communications. 383: 450-4. PMID 19371722 DOI: 10.1016/j.bbrc.2009.04.031  0.36
2009 Neal CL, Yao J, Yang W, Zhou X, Nguyen NT, Lu J, Danes CG, Guo H, Lan KH, Ensor J, Hittelman W, Hung MC, Yu D. 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Research. 69: 3425-32. PMID 19318578 DOI: 10.1158/0008-5472.CAN-08-2765  0.36
2009 Hung MC, Mills GB, Yu D. Oxygen sensor boosts growth factor signaling. Nature Medicine. 15: 246-7. PMID 19265822 DOI: 10.1038/nm0309-246  0.52
2009 Lu J, Tan M, Huang WC, Li P, Guo H, Tseng LM, Su XH, Yang WT, Treekitkarnmongkol W, Andreeff M, Symmans F, Yu D. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1326-34. PMID 19228734 DOI: 10.1158/1078-0432.CCR-08-0954  1
2008 Torti FM, Altieri D, Broach J, Fan H, Lotze M, Manfredi J, Matrisian L, Yu D, Giaccia A. Ph.D. training in cancer biology Cancer Research. 68: 9122-9124. PMID 19010881 DOI: 10.1158/0008-5472.CAN-08-2626  0.36
2008 Danes CG, Wyszomierski SL, Lu J, Neal CL, Yang W, Yu D. 14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling. Cancer Research. 68: 1760-7. PMID 18339856 DOI: 10.1158/0008-5472.CAN-07-3177  0.36
2008 Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, Huang H, Kuo HP, Lee DF, Li LY, Lien HC, ... ... Yu D, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nature Cell Biology. 10: 138-48. PMID 18204439 DOI: 10.1038/ncb1676  0.52
2008 Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast RC, Hortobagyi GN, Hung MC. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Molecular Carcinogenesis. 47: 701-6. PMID 18176935 DOI: 10.1002/mc.20413  0.52
2007 Liao Y, Yu D, Hung MC. Novel approaches for chemosensitization of breast cancer cells: the E1A story. Advances in Experimental Medicine and Biology. 608: 144-69. PMID 17993239  0.44
2007 Tan M, Yu D. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Advances in Experimental Medicine and Biology. 608: 119-29. PMID 17993237  1
2007 Lu CH, Wyszomierski SL, Tseng LM, Sun MH, Lan KH, Neal CL, Mills GB, Hortobagyi GN, Esteva FJ, Yu D. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5883-8. PMID 17908983 DOI: 10.1158/1078-0432.CCR-06-2837  0.36
2007 Hannay JA, Liu J, Zhu QS, Bolshakov SV, Li L, Pisters PW, Lazar AJ, Yu D, Pollock RE, Lev D. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Molecular Cancer Therapeutics. 6: 1650-60. PMID 17513613 DOI: 10.1158/1535-7163.MCT-06-0636  0.36
2007 Das P, Kotilingam D, Korchin B, Liu J, Yu D, Lazar AJ, Pollock RE, Lev D. High prevalence of p53 exon 4 mutations in soft tissue sarcoma. Cancer. 109: 2323-33. PMID 17429838 DOI: 10.1002/cncr.22680  0.36
2006 De Clerck YA, Weissman BE, Yu D, Parsons R, Bar-Eli M, Roy-Burman P, Seewaldt VL, Cress AE, Languino LR, Batra SK, Tang CK, Sheng S, Chen WT, Chellappan S, Cheng SY, et al. Tumor progression and metastasis from genetic to microenvironmental determinants: a workshop of the tumor progression and metastasis NIH study section in honor of Dr. Martin L. Padarathsingh, May 31, 2006, Georgetown, Washington, DC. Cancer Biology & Therapy. 5: 1588-99. PMID 17224636  0.36
2006 Lu J, Yu D. Adenoviral-Vector Based siRNA for Mutant K-ras as a Promising Tool for Lung Cancer Gene Therapy: A License to Kill. Cancer Biology & Therapy. 5: 1724-5. PMID 17224631  0.52
2006 Liu J, Zhan M, Hannay JA, Das P, Bolshakov SV, Kotilingam D, Yu D, Lazar AF, Pollock RE, Lev D. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis. Molecular Cancer Research : McR. 4: 803-10. PMID 17077165 DOI: 10.1158/1541-7786.MCR-06-0201  0.36
2006 Ping B, He X, Xia W, Lee DF, Wei Y, Yu D, Mills G, Shi D, Hung MC. Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKbeta overexpression in human breast cancers. International Journal of Oncology. 29: 1103-10. PMID 17016640  0.44
2006 Zhang L, Hannay JA, Liu J, Das P, Zhan M, Nguyen T, Hicklin DJ, Yu D, Pollock RE, Lev D. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Cancer Research. 66: 8770-8. PMID 16951193 DOI: 10.1158/0008-5472.CAN-06-1217  0.36
2006 Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clinical Practice. Oncology. 3: 269-80. PMID 16683005 DOI: 10.1038/ncponc0509  0.44
2006 Tan M, Lan KH, Yao J, Lu CH, Sun M, Neal CL, Lu J, Yu D. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Research. 66: 3764-72. PMID 16585203 DOI: 10.1158/0008-5472.CAN-05-2747  0.36
2006 Konopleva M, Zhang W, Shi YX, McQueen T, Tsao T, Abdelrahim M, Munsell MF, Johansen M, Yu D, Madden T, Safe SH, Hung MC, Andreeff M. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Molecular Cancer Therapeutics. 5: 317-28. PMID 16505105 DOI: 10.1158/1535-7163.MCT-05-0350  0.44
2006 Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN, Yu D. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Research. 66: 2028-37. PMID 16489002 DOI: 10.1158/0008-5472.CAN-04-4559  1
2006 Tan M, Li P, Sun M, Yin G, Yu D. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene. 25: 3286-95. PMID 16407820 DOI: 10.1038/sj.onc.1209361  1
2006 Efferson CL, Tsuda N, Kawano K, Nistal-Villán E, Sellappan S, Yu D, Murray JL, García-Sastre A, Ioannides CG. Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells. Journal of Virology. 80: 383-94. PMID 16352563 DOI: 10.1128/JVI.80.1.383-394.2006  0.52
2005 Lan KH, Lu CH, Yu D. Mechanisms of trastuzumab resistance and their clinical implications. Annals of the New York Academy of Sciences. 1059: 70-5. PMID 16382045 DOI: 10.1196/annals.1339.026  0.52
2005 Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y, Fang D, Jing T, Yu D. ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Research. 65: 1858-67. PMID 15753384 DOI: 10.1158/0008-5472.CAN-04-2353  1
2005 Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA, Wharton SB, Jellinek DA, Arbuckle SM, Yoo J, Robinson BG, Learoyd DL, Stalley PD, Bonar SF, Yu D, et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 217-25. PMID 15671549  0.36
2005 Thomas DG, Giordano TJ, Sanders D, Biermann S, Sondak VK, Trent JC, Yu D, Pollock RE, Baker L. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer. 103: 830-8. PMID 15641030 DOI: 10.1002/cncr.20847  0.36
2005 Zhan M, Yu D, Liu J, Glazer RI, Hannay J, Pollock RE. Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation. The Journal of Biological Chemistry. 280: 4825-33. PMID 15563462 DOI: 10.1074/jbc.M407450200  0.36
2004 Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, Hung MC. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 6: 459-69. PMID 15542430 DOI: 10.1016/j.ccr.2004.09.027  1
2004 Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6779-88. PMID 15501954 DOI: 10.1158/1078-0432.CCR-04-0112  1
2004 Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 6: 117-27. PMID 15324695 DOI: 10.1016/j.ccr.2004.06.022  1
2004 Hawthorne VS, Yu D. PI3K: Missense Mutation Motivates Malignancy. Cancer Biology & Therapy. 3: 776-7. PMID 15280668  0.56
2004 Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB, Yu D. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Research. 64: 3479-85. PMID 15150101 DOI: 10.1158/0008-5472.CAN-3299-2  1
2004 Klos KS, Yu D. Liposomal mediated transfer of ErbB2 antisense DNA: coming of age in the war against cancer. Cancer Biology & Therapy. 3: 205-6. PMID 14764991  1
2003 Hannay JA, Yu D. Silibinin: a thorny therapeutic for EGF-R expressing tumors? Cancer Biology & Therapy. 2: 532-3. PMID 14614321 DOI: 10.4161/cbt.2.5.536  0.36
2003 Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer. 98: 1377-85. PMID 14508823 DOI: 10.1002/cncr.11656  1
2003 Yang W, Klos KS, Zhou X, Yao J, Yang Y, Smith TL, Shi D, Yu D. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression. Cancer. 98: 1123-30. PMID 12973835 DOI: 10.1002/cncr.11625  1
2002 Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Research. 62: 5703-10. PMID 12384528  0.52
2002 Hu M, Nicolson GL, Trent JC, Yu D, Zhang L, Lang A, Killary A, Ellis LM, Bucana CD, Pollock RE. Characterization of 11 human sarcoma cell strains: evaluation of cytogenetics, tumorigenicity, metastasis, and production of angiogenic factors. Cancer. 95: 1569-76. PMID 12237927 DOI: 10.1002/cncr.10879  0.36
2002 Yang W, Klos K, Yang Y, Smith TL, Shi D, Yu D. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer. 94: 2855-61. PMID 12115372 DOI: 10.1002/cncr.10553  0.52
2002 Tan M, Jing T, Lan KH, Neal CL, Li P, Lee S, Fang D, Nagata Y, Liu J, Arlinghaus R, Hung MC, Yu D. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Molecular Cell. 9: 993-1004. PMID 12049736 DOI: 10.1016/S1097-2765(02)00510-5  0.36
2002 Zhang L, Yu D, Hicklin DJ, Hannay JA, Ellis LM, Pollock RE. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Research. 62: 2034-42. PMID 11929822  0.36
2001 Yao J, Xiong S, Klos K, Nguyen N, Grijalva R, Li P, Yu D. Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene. 20: 8066-74. PMID 11781819 DOI: 10.1038/sj.onc.1204944  1
2001 Xiong S, Grijalva R, Zhang L, Nguyen NT, Pisters PW, Pollock RE, Yu D. Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration. Cancer Research. 61: 1727-32. PMID 11245489  1
1999 Tan M, Grijalva R, Yu D. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase. Cancer Research. 59: 1620-5. PMID 10197638  1
1998 Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ, Hung MC. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Molecular Cell. 2: 581-91. PMID 9844631  1
1998 Pollock R, Lang A, Ge T, Sun D, Tan M, Yu D. Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 4: 1985-94. PMID 9717829  1
1998 Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, Ibrahim N, Hortobagyi GN, Hung MC. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene. 16: 2087-94. PMID 9572489 DOI: 10.1038/sj.onc.1201729  0.36
1998 Yao J, Pollock RE, Lang A, Tan M, Pisters PW, Goodrich D, El-Naggar A, Yu D. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 4: 1065-70. PMID 9563903  1
1997 Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Research. 57: 1199-205. PMID 9067293  1
1996 Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. 13: 1359-65. PMID 8808711  1
Show low-probability matches.